US45253H1014 - Common Stock
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.
Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings.
Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.
AbbVie updates its earnings outlook for Q1 2024, reflecting a dilutive impact from the completed acquisition of ImmunoGen.
Adds flagship antibody-drug conjugate (ADC) ELAHEREĀ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRĪ±) positive platinum-resistant ovarian...
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
ImmunoGen's (IMGN) all-cash deal acquisition by AbbVie (ABBV) is set to be completed next week after the expiration of the Hart-Scott-Rodino waiting period. Read more here.
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge.
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.
China has become a dominant player in the antibody-drug conjugate (ADC) race, attracting Western pharmaceutical companies for partnerships. Read more here.
AbbVie is set to report its Q4 2023 results amid one year anniversary of biosimilar competition against its blockbuster arthritis therapy Humira. Read more here.
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses.
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024.
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
The company is grappling with losing Humira's patent protection in 2023.
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.
Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
The acquisition fills an immediate need with some extras to boot.
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.
Merger and acquisition activity is set to rise in the coming year as borrowing becomes easier and companies are undeterred by antitrust regulators, signaling...